Wave Life Sciences announces positive results from SELECT-HD
Earlier this week, Wave Life Sciences shared a positive update from the Phase 1b/2a study, SELECT-HD. The study is testing a spinally-delivered ASO drug that focuses on lowering only the harmful form of huntingtin protein, while preserving healthy huntingtin. In a very small group of initial participants who received low doses of the drug, WVE-003, Wave has observed safe and selective lowering of mHTT in spinal fluid. This means that the drug appears to be hitting the intended target, which is great news. They did also observe an increase in levels of a protein called NfL, which can indicate damage or inflammation – but the main finding is that WVE-003 seems safe, tolerable, and is lowering harmful huntingtin. Wave will continue to monitor NfL as the trial progresses, along with many other signs of safety and efficacy. To read the full press release from Wave, click here.
Roche will begin enrolling participants for GENERATION-HD2 in early 2022
Earlier this week, during the EHDN conference in Bologna, Italy, Roche announced it expects to begin enrolling participants in a new Phase 2 study called GENERATION HD-2 in early 2023. The study will test the effects of the experimental huntingtin-lowering drug, tominersen, on 360 individuals with early-stage HD. To read the full community letter from Roche, click here. To read a perspective on the new trial from a community advocate, click here for the newest blog post from Gene Veritas.
Online Study: Experiences of those who have received negative genetic testing results for HD
A genetic counseling graduate student from Kean University is conducting research on the experiences and psychosocial effects of individuals 18 and older who have received negative predictive testing results for HD in the last 10 years. Investigating this topic will be beneficial to address the current knowledge gap and help identify how genetic counselors can better support these individuals during the post-test counseling process. The study consists of participating in a Zoom interview with the researcher. The interview will last approximately 30 minutes to one hour. If you are interested in participating, click here to review the informed consent, and click here to sign up for an interview and make your voice heard. Click here to learn more.